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measurements (GLM) to compare the groups. The trial was ap-
proved by the regional ethics committee in Norway, Norwegian
Medicines Agency and the Norwegian Data Inspectorate. All pro-
cedures conformed to the Declaration of Helsinki. The trial was
registered at http://www.clinicaltrials.gov under the identiﬁer NCT
0040407. The trial was initiated by Ulleval University Hospital and
ﬁnanced by the Norwegian LBP organization and not producer
ﬁnanced.
Results: This is an interim analysis only. Mean age of the patients
(n=250) was 48,5 years. 48.4% were women. Lost to follow up at 6
months was 18 and equal in both groups. GS was not signiﬁcantly
better than placebo in reducing RMDQ score by 3 points. Repeated
measurements (GLM) demonstrated no difference between the
glucosamine- and the placebo-group. None of the secondary
outcomes (NPS, EQ-5D etc) demonstrated any difference between
the groups. RMDQ, NPS, LBP duration, race, age, sex, weight,
height, BMI, EQ-5D and HSCL-25 were similar in both groups at
baseline. No changes in fasting plasma glucose and cholesterol
levels were observed post trial participation in either treatment
arm. Adverse events were mild, rare and equally distributed among
the two groups.
Conclusions: Interim results show that daily intake of glu-
cosamine sulfate for 6 months was not effective in reducing low
back pain measured with RMDQ.
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TO VALGUS BRACING IN THE TREATMENT OF MEDIAL
COMPARTMENTAL OSTEOARTHRITIS OF THE KNEE:
A PROSPECTIVE RANDOMIZED TRIAL
T.M. van Raaij1, M. Reijman1, R.W. Brouwer2,
S.M. Bierma-Zeinstra1, J.A. Verhaar1
1Erasmus MC, Rotterdam, Netherlands; 2Martini Hosp.,
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Purpose: The goal was to study the effect of a lateral-wedged
insole compared to valgus bracing in patients with symptomatic
medial compartmental knee osteoarthritis (OA).
Methods: Consecutive patients with symptomatic medial com-
partmental knee OA who visited the orthopaedic outpatient de-
partment of a university medical center were eligible for inclusion.
Patients with symptoms not related to medial compartmental OA,
younger than 35 years of age, an insufﬁcient command of the
Dutch language, or no varus malalignment were excluded. The
degree of knee alignment (hip-knee-ankle angle) was assessed
on a digitalized whole leg radiograph in standing position. After
written informed consent patients were randomly assigned to ei-
ther an intervention group comprising a shoe inserted leather sole
with a lateral-wedged cork elevation of 10 millimeters (6° wedge),
or to a control group comprising a commercially available valgus
knee brace. The allocation of treatment was concealed until after
the participants were included and baseline measurements were
executed. One assessor performed all baseline and 6 months
follow-up measurements.Primary outcome measure was change
in pain severity (VAS). Besides knee function scores (HSS, KSS,
WOMAC), percentage responders, varus alignment correction in
the frontal plane using the hip-knee-ankle angle, and compliance
to the intervention. Responders to the intervention were deﬁned
as having an improvement of ≥ 20% compared to the baseline
score for pain and function.
Results: Between January 2006 and September 2007, 91 con-
secutive patients were included and randomized (45 insole group;
46 brace group). Pain severity scores improved more in the insole
group compared with the bracing group for VAS (-.09; 95% CI:
-1.31; 1.13; effect size 0.04) and WOMAC pain score (.13; 95%CI:
-9.43; 9.18; effect size 0.004). Knee function was better for the
insole group for HSS score (1.69; 95% CI: -3.17; 6.55, effect size
0.16), KSS score (5.47; 95% CI: -12.48; 1.53, effect size 0.34),
and WOMAC function score (1.43; 95% CI: -9.39; 6.53, effect
size 0.07). There were no signiﬁcant differences in percentages
of responders between the insole and the brace groups (27% vs
25%, respectively).Both intervention had no impact on the varus
malalignment. At 6 months 71% of patients in the insole group
complied with the intervention, which was signiﬁcantly (p = 0.015)
higher compared to 45% for the brace group.
Conclusions: We found no differences in effectiveness of both a
6° lateral-wedged leather shoe inlay and a commercially available
valgus brace in the treatment of patients with symptomatic medial
OA of the knee joint after 6 months. According to the OMERACT-
OARSI set of responder criteria for clinical trials in OA, however,
only one fourth of all patients beneﬁted from either the insole or
brace intervention.
321
A RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND,
PLACEBO AND NAPROXEN CONTROLLED, MULTICENTER
PHASE 3 STUDY OF NAPROXCINOD IN SUBJECTS WITH
OSTEOARTHRITIS OF THE KNEE: EFFICACY RESULTS
FOLLOWING 13-WEEK TREATMENT
C.E. Marrero1, C. Tuten2, T. Shamim3, V. Awasty4, J. Agaiby5,
D. Hassman6, J. Sutphen7, H. Frayssinet8, B. Duquesroix8
1Deep South Clinical Res., Nederland, TX; 2Clinical Ctr. of
Asheville, Asheville, NC; 3Heartland Clinical Res., Omaha, NE;
4R&R Res., Marion, OH; 5Clinical Investigation Specialist, Inc,
Gurnee, IL; 6Comprehensive Clinical Res., Berlin, NJ; 7NicOx,
Warren, NJ; 8NicOx, Sophia Antipolis, France
Purpose: Naproxcinod is a Cyclooxygenase Inhibiting Nitric Ox-
ide Donator (CINOD) under development for the relief of signs
and symptoms of OA. Naproxcinod exerts its activity through its
two primary metabolites: naproxen and the NO donating moiety.
In previous clinical trials, naproxcinod has shown similar anti-
inﬂammatory and analgesic efﬁcacy to conventional NSAIDs, and
an improved BP safety and tolerability proﬁle, likely due to its NO
donation.
The primary objective of the study was to show that naproxcinod
375 mg bid and 750 mg bid were superior to placebo in relieving
signs and symptoms in subjects with OA of the knee after 13
weeks of treatment.
Methods: In this placebo 13-week and naproxen 26-week con-
trolled study, men and women 40+ years old with a diagnosis
of primary OA of the knee meeting ACR criteria and experienc-
ing a ﬂare of pain at baseline after discontinuation of previous
anti-inﬂammatory or acetaminophen treatments were randomized
(1:1:1:1) to either naproxcinod 375 mg or 750 mg bid, naproxen
500 mg bid or placebo bid. The three co-primary efﬁcacy variables
were the mean change from Baseline at Week 13 in WOMAC™
pain and function subscale scores and subject’s global assess-
ment of disease status. The superiority analysis of naproxcinod
over placebo was the primary efﬁcacy analysis.
The analysis of each primary efﬁcacy variable was based on
an analysis of covariance (ANCOVA) with treatment group as
factor, and baseline value as covariate. The primary efﬁcacy
analysis was performed using the Intent-to-Treat (ITT) population
(all randomized subjects) and was performed on as-randomized
basis.
Results: A total of 1011 subjects from 129 US centers were
included in the ITT population. 71.0% of subjects were female,
78.9% were Caucasian. The mean age was 59.8 years and mean
BMI 33.8 kg/m2. A total of 766 (75.8%) subjects completed the 13
week study period.
Both doses of naproxcinod (375 mg bid and 750 mg bid) demon-
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strated superior efﬁcacy to placebo in the three co-primary end-
points of WOMAC™ pain and function, and subject’s overall rating
of disease status (p≤0.0004). In addition, naproxcinod 750 mg bid
was non-inferior to naproxen 500 mg bid at Week 13.
The percentage of subjects with at least one treatment emergent
AE was 47.0%, 46.4%, for naproxcinod 375 and 750 mg bid,
respectively, 47.7% for naproxen and 44.8% for placebo.
Conclusions: This study demonstrated the clinical efﬁcacy of
naproxcinod 375 mg bid and 750 mg bid over placebo after 13
weeks of treatment, conﬁrming the results of previous clinical
trials. Both doses of naproxcinod were safe and well tolerated.
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Purpose: To evaluate the long-term safety of tanezumab, a hu-
manized monoclonal antibody speciﬁc for nerve growth factor, in
patients with knee pain due to osteoarthritis (OA).
Methods: Male and female patients aged 40-78 years who had
received 2 infusions of tanezumab in a Phase II, 16 week, placebo-
controlled multiple-dose study (Study 1008) and been followed for
≥8 weeks after the last infusion, were eligible to enrol in this
open-label extension study to evaluate the long-term safety and
efﬁcacy of tanezumab for the treatment of osteoarthritic knee pain.
Patients received tanezumab 50 μg/kg (IV) on Days 1 and 56, and
at subsequent 8 week intervals at the discretion of the investigator.
Safety assessments including adverse event (AE) documentation,
physical and neurological examinations, Hopkins Verbal Learning
Test-Revised (HVLT-R), vital signs, blood tests, urinalysis and 12-
lead ECG were performed at each visit until termination, 12 weeks
after the last dose of tanezumab. Patients who received ≥1 study
drug infusion (in this study) were included in the safety analysis.
Results: Of 281 patients assigned to open-label treatment, similar
numbers came from each treatment arm (placebo or tanezumab
10, 25, 50, 100 or 200 μg/kg) of Study 1008. Patients were 39%
male, 89% white, with a mean (±SD) age of 59 (±8.1) years. They
received between 1 and 8 infusions of 50 μg/kg tanezumab over a
mean (±SD) period of 224 (±117) days (range 1-484 days). Over-
all, 168 (59.8%) patients reported 446 all-cause AEs, of which the
most frequently reported (>5% of patients) were arthralgia (6.8%),
back pain (6.0%), and headache (5.7%). All-cause AEs suggestive
of abnormal peripheral sensation (hyperaesthesia, hypoaesthesia,
peripheral neuropathy, paraesthesia, sensory disturbance) were
reported by 18 (6.4%) patients, in 17 of whom the AE was mild in
intensity and in 1 of whom it was severe (peripheral neuropathy).
Hypoesthesia (3.2%) was the most frequent AE suggestive of
abnormal peripheral sensation. Allodynia and dysaesthesia were
not reported by any patient. In total, 21 (7.5%) patients reported
28 treatment-related AEs, of which the most frequent (≥2 pa-
tients) were hypoaesthesia (1.1%), paraesthesia (1.1%), dizziness
(0.7%), and peripheral oedema (0.7%). Of the 19 (6.8%) patients
who discontinued treatment due to an AE, 4 discontinued due to
treatment-related AEs (hypoaesthesia; adjustment disorders with
depressed mood; diarrhoea; and prolonged ECG QT). No vital
sign, physical, or neurological examination was reported as an
AE and there was no notable decrease in mean change from
baseline in total and delayed recall HVLT-R scores. A serious AE
(SAE), irrespective of causality, was reported by 8 (2.8%) patients,
but none was considered to be treatment-related. There were no
deaths. In addition, pain relief (improvement in overall knee pain
and walking pain) was maintained during open-label treatment of
up to 1 year in duration.
Conclusions: Repeat doses of tanezumab 50 μg/kg, given to
patients with moderate to severe osteoarthritic knee pain were
safe and well tolerated over the long term. AEs suggestive of
abnormal peripheral sensation were transient and almost all were
mild in intensity. Tanezumab also provided sustained and effective
analgesia.
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Purpose: Knee OA in its most severe form is a wasting disease
that causes pain, stiffness and disability. As there are no known
cure for OA the treatment is aimed at symptoms by use of pain
killers, NSAIDs, physiotherapy and braces. Osteotomies where the
load on the symptomatic compartment of the knee is reduced by
changing alignment in the knee is a alternative. In severe OA joint
replacement is often the only choice.
Unloader (valgus) braces are designed to decrease the load on the
symptomatic compartment of the OA knee by changing alignment.
This should reduce pain and improve function. The purpose of this
study is to document outcomes following 6 months of use of an
Unloader brace in a cohort of patients with knee OA.
Methods: Patients who were diagnosed by orthopedic surgeons,
general practitioners and rheumatologists with knee OA and had
prescription for Unloader brace because of unicompartmental
symptomatic knee OA were enrolled in the study. The knee
OA was graded according to Kellgrene & Lawrence classiﬁcation
from weight bearing radiographs of both knees (P/A weight bear-
ing/semi ﬂexed and lateral supine). Patients with mild, moderate
or severe unicompartmental knee OA and even patients who were
waiting for knee arthroplasty were included. The WOMAC index
(version 3.1) was the main instrument used to assess the severity
of the symptoms. This consists of 24 items in 3 subscales: pain
(5), stiffness (2), and physical function (17). Component items are
measured on a 5-point Likert scale with higher scores indicating
greater symptom severity.
It was an IRB approved prospective cohort study and the pa-
tients signed informed consent before answering questionnaires.
First before receiving the Unloder then after 3 weeks, 3 months
and 6 months. The main outcomes in the analysis were the
three WOMAC subscale scores (pain, stiffness, function) and the
combined Total WOMAC score. Exposure variables considered in
analyses were: Age, Gender, BMI and K& L grade (0, 1, 2, 3, 4).
Results: 82 patients participated in the study. 33 women mean
age 59.7 years (40-81), 49 men average age 60.9 years (38-85).
Mean BMI (SD) in men was 30.3 (±5.0) and in women 31.0 (±6.1).
Five patients discontinued using the brace because of pain during
the study. Three patients only answered the ﬁrst questionnaire.
Eight patients were on waiting lists for knee arthroplasty when the
brace where prescribed and 5 of them where operated during the
study time. 75 of the patients had radiographic medial knee OA
and according to the K&L classiﬁcation, 13 grade I, 25 grade II, 32
grade III and 11 grade IV. Seven patients had radiographic lateral
knee OA, 4 grade III and 3 grade II. Seventy-ﬁve were prescribed
a medial Unloader brace and seven lateral.
Total WOMAC score at baseline was 50 and decreased to 34 after
three week. The improvement continued for six months. This is a
